SCHEMBL20007365

SCHEMBL20007365

CN(C(=O)C(Cc1cc(F)cc(F)c1)NC(=O)NS(=O)(=O)Nc1cccc(Cl)c1)c1ccc2scnc2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.35
KMT2A Q03164 5/20 0.35
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
LIMK2 P53671 1/20 0.33
MAPK1 P28482 2/20 0.33
CTPS1 P17812 4/20 0.32
NAMPT P43490 1/20 0.32
MAPT P10636 4/20 0.32
LMNA P02545 2/20 0.32
USP2 O75604 1/20 0.32
EGFR P00533 2/20 0.32
NPY1R P25929 1/20 0.31
OPRM1 P35372 1/20 0.31
HSD11B1 P28845 1/20 0.31
TP53 P04637 1/20 0.31
TSHR P16473 1/20 0.31
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18181118 1.00 MEN1 (0.35) MEN1KMT2ANPC1RAB9AL3MBTL1
SCHEMBL20007636 0.92 MAPK1 (0.34) MEN1KMT2ANPC1RAB9AMAPK1
SCHEMBL18181128 0.92 MAPK1 (0.34) MEN1KMT2ANPC1RAB9AMAPK1
SCHEMBL18181431 0.88 NAMPT (0.40) MEN1KMT2AL3MBTL1NAMPT
SCHEMBL18181071 0.88 ALDH1A1 (0.37) NPC1RAB9AMAPK1MAPTSMN1; SMN2
SCHEMBL19999762 0.87 MEN1 (0.33) MEN1KMT2ANPC1RAB9AL3MBTL1
SCHEMBL19969198 0.86 SYK (0.31)
SCHEMBL18180271 0.86 SYK (0.31)
SCHEMBL20007601 0.86 NTRK1 (0.34) MAPK1SMN1; SMN2NPSR1
SCHEMBL18181165 0.86 NTRK1 (0.34) MAPK1SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286166-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2020-05-13 EP disclosed
US-10221129-B2 Inhibitors of human immunodeficiency virus replication VIIV Healthcare UK (No.5) Limited (GB) 2019-03-05 US disclosed
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10221129-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR2E, POLR2H MEN1 4300/4885KMT2A 3450/4885NPC1 209/4885
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2E, POLR2H MEN1 4300/4885KMT2A 3450/4885NPC1 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.